AZ blames UK tax for Ireland API plant decision
The company’s CEO stated that a ‘discouraging tax rate’ was behind the decision to build a $360m API plant in Ireland rather than the UK.
The company’s CEO stated that a ‘discouraging tax rate’ was behind the decision to build a $360m API plant in Ireland rather than the UK.
SCOPE 2023
The company published a report finding that almost a fifth of trial sites only recruit one patient, Phesi’s CEO explained to Outsourcing-Pharma what the reaction at the event had been.
SCOPE 2023
The two companies will come together to provide a ‘patient-centered solution’ for clinical research, combing uMotif’s patient engagement platform with ActiGraph’s wearable technology.
A Danish company has taken a step closer to making available a cream to treat moderate to severe, chronic hand eczema (CHE).